COVID-19
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus, originated from the Wuhan region of Hubei province in China late in 2019.
AffinityImmuno has been involved in developing research tools to accelerate the fight against SARS-CoV-2 since February 2020 when we performed our first immunizations to generate research antibodies.
COVID-19 Spike Protein Antibodies
AffinityImmuno was among the first suppliers of antibodies to SARS-CoV-2 by immunizing our lay hen flock beginning in February 2020 to generate polyclonal antibodies to:
COVID-19 Spike Antibody
ab-131-291
COVID-19 Spike S1 Antibody
ab-131-292
COVID-19 Spike S2 Antibody
ab-131-293
Affinity purified and antibody pairs
In addition to bulk polyclonal antibodies, we have the following affinity purified and antibody pairs:
5 Kits – COVID-19 Spike Capture and Detection (HRP conjugate) ELISA pair with calibrator
ab-131-295-PAIR
Affinity Purified SARS-COV-2 Spike S2 Domain Antibody
ab-131-294
Gold Conjugated Affinity Purified SARS-COV-2 Spike S2 Domain Antibody
ab-131-294-gold
HRP Conjugated Affinity Purified SARS-COV-2 Spike S2 Domain Antibody
ab-131-294-hrp
Virus Neutralization Test
SARS-CoV-2 surrogate Virus Neutralizing Test (sVNT) (spike protein/ ACE2 ligand binding assay) COVID-19 sVNT
EL-1611-32214
